Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

Liminatus Pharma, Inc. (NASDAQ: LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum ...

Royalty Pharma Plc (NASDAQ: RPRX) is one of the most profitable biotech stocks to buy. On October 10, Morgan Stanley analyst ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Learn more about whether BioMarin Pharmaceutical Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

We recently published 10 Trending Stocks This Week. SPDR S&P Biotech ETF (NYSEARCA:XBI) is one of the trending stocks this ...

It appears the pharmaceutical industry may avoid threatened tariffs. An exchange-traded fund (ETF) is a great way to invest in major drugmakers. Now may be the time to invest in drug companies, as ...

How a US SOL ETF could shift access, flows and usage — plus the key metrics to watch to see whether Solana outperforms Ether. ETH ETFs have opened access, but flows remain cyclical. SOL’s plumbing is ...